Synthetic STING agonists, used in conjunction with ICIs, cancer vaccines and adoptive T-cell transfer therapies are emerging as promising therapeutic options with the potential to enhance the effectiveness of cancer treatments and improve patient outcomes. The gene discussed is STING1; the disease is cancer.